Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer

Dl, Zheng; Gd, Tang; Yn, Chen; T, Zhang; Mb, Qin

doi:10.4238/gmr.15027384

Cited by 5 publications

(5 citation statements)

References 20 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main characteristics of included studies are presented in Table 2 . 13 – 22 The distribution of genotypes in the control groups of all studies was in agreement with HWE except three. 18 , 20 , 21 A total of 10 studies were performed in Chinese populations.…”

Section: Resultssupporting

confidence: 67%

“…This was inconsistent with the conclusion of some previous studies. Zheng et al 13 have reported that the AA genotype of ERCC1 rs3212986 was associated with lower rates of complete remission and partial remission following chemotherapy in GC patients. Similarly, Bai et al 16 discovered that patients carrying the GT and TT genotypes of rs3212986 showed a significantly poorer response to chemotherapy than did those carrying the GG genotype.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

<em>ERCC1</em> rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations

Tang

Wang

et al. 2017

OTT

View full text Add to dashboard Cite

BackgroundA number of studies have investigated the roles of excision repair cross-complementation group 1 (ERCC1) gene rs3212986 polymorphisms as potential biomarkers in gastric cancer (GC). However, the results were inconsistent. Here, we performed a meta-analysis to explore ERCC1 rs3212986 polymorphisms in the chemotherapy response and clinical outcome of GC.MethodsPubMed, Embase, and Web of Science were searched up to July 28, 2017, for studies on the association between ERCC1 rs3212986 A/C polymorphisms and response to chemotherapy as well as overall survival time of GC. A fixed-effect or random-effect model was used to calculate the pooled odds ratios (ORs) based on the results from the heterogeneity tests.ResultsThe result revealed that there was no significant association between the ERCC1 rs3212986 A/C polymorphism and response to chemotherapy in GC under comparison models (AA + CA versus CC, OR 0.95, P=0.80, AA versus CA, OR 0.85, P=0.55, AA versus CC, OR 0.74, P=0.47). Further identification suggested that ERCC1 rs3212986 A/C polymorphisms were not linked with the overall survival of GC (AA + CA versus CC, OR 1.09, P=0.52, AA versus CA, OR 1.05, P=0.85, AA versus CC, OR 1.43, P=0.23).ConclusionOur meta-analysis indicated that the ERCC1 rs3212986 A/C polymorphism was not associated with response to chemotherapy or overall survival time in GC. Well-designed studies with larger sample sizes and more ethnic groups should be performed to further validate our results.

show abstract

Section: Resultssupporting

confidence: 67%

Section: Discussionmentioning

confidence: 99%

<em>ERCC1</em> rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations

Tang

Wang

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…Several researchers have reported a relationship between ERCC2 rs13181 and rs1799793 polymorphisms and chemotherapy efficacy in gastric cancer patients [12–24]. In 2014, a study by Yu et al revealed that the AA genotype of the ERCC2 rs1799793 polymorphism is associated with better response to chemotherapy in gastric cancer patients [19].…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, many researchers have investigated possible relationships between two ERCC2 polymorphisms, rs13181 and rs1799793, and treatment response and prognosis, which are indicators of chemotherapy efficacy, in patients with gastric cancer [12–24]; however, most of these studies have been inconclusive. Therefore, this meta-analysis was conducted to evaluate the abovementioned relationships.…”

Section: Introductionmentioning

confidence: 99%

Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis

Zhao

et al. 2018

Disease Markers

View full text Add to dashboard Cite

Background Several researchers have investigated the relationship between ERCC2 rs13181 and rs1799793 polymorphisms and chemotherapy efficacy in terms of tumour response and prognosis in gastric patients. However, the published data have shown inconsistencies. Methods PubMed, Elsevier, and Chinese National Knowledge Infrastructure databases were searched for relevant articles published before August 1, 2017. Thirteen studies including 3096 gastric cancer patients treated with chemotherapy were included. Results For rs1799793, in the overall analyses, no relationships were found between four genetic models and clinical response (AA vs. GG: OR = 1.17, 95% CI, 0.70–1.95; GA vs. GG: OR = 0.94, 95% CI, 0.69–1.27; GA + AA vs. GG: OR = 1.12, 95% CI, 0.85–1.46; and AA vs. GG + GA: OR = 1.24, 95% CI, 0.81–1.92). In stratified analyses, the results remained negative. We also found no relationship between each of the genetic models and overall survival time in the overall analyses. In the stratified analyses, for Asians, the A carrier genotype might be more closely associated with shorter survival time and higher risk of death for patients than the GG genotype (AA vs. GG: HR = 1.77, 95% CI, 1.20–2.6; GA + AA vs. GG: HR = 1.62, 95% CI, 1.26–2.09), but the results were negative for Caucasians. No significant relationships were found between the rs13181 polymorphism and OR or OS. Conclusions This meta-analysis suggested that the ERCC2 rs1799793 polymorphism might be a predictor of prognosis in gastric cancer patients subjected to platinum-based chemotherapy.

show abstract

“…However, we did not find any direct association of the rs4134822 and rs1799793 with NMSC risk after covariates adjustment. Previously, many studies have focused on the association between NER gene and some other diseases, including prostate cancer [ 19 ], gastric cancer [ 20 ] and thyroid cancer [ 21 ]. Several studies [ 11 – 15 ] were also performed on association between SNPs within NER gene and NMSC risks, but the limited number for these articles could not concluded a consistent result on this association, and could not clarify the mechanism between NER gene and NMSC susceptibility.…”

Section: Discussionmentioning

confidence: 99%

A case-control study on association of nucleotide excision repair polymorphisms and its interaction with environment factors with the susceptibility to non-melanoma skin cancer

Wang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

AimsTo investigate the association of several single nucleotide polymorphisms (SNPs) within nucleotide excision repair (NER) gene and additional gene- gene and gene- smoking interaction with non-melanoma skin cancer (NMSC) risk in a Chinese population.MethodsA total of 1322 participants (939 males, 383 females) were selected, including 660 NMSC patients and 662 control participants. Generalized multifactor dimensionality reduction (GMDR) was used to screen the best interaction combination among SNPs and smoking. Logistic regression was performed to investigate association between 4 SNPs within NER gene, additional gene- gene and gene- smoking interaction on NMSC risk.ResultsNMSC risk was significantly higher in carriers with G allele of rs2228527 than those with AA genotype (AG + GG versus AA), adjusted OR (95%CI) =1.76 (1.24-2.37), and higher in carriers with the G allele of rs2228529 than those with AA genotype (AG + GG versus AA), adjusted OR (95%CI) = 1.66 (1.24-2.13). However, we did not find any direct association of the rs4134822 and rs1799793 with NMSC risk after covariates adjustment. GMDR model indicated a significant interaction combination (p=0.0010), including rs2228529 and current smoking. Overall, the cross-validation consistency of this model was 9/ 10, and the testing accuracy was 60.72%. Current smokers with rs2228529- GA or GG genotype have the highest NMSC risk, compared to never- smokers with rs2228529- AA genotype, OR (95%CI) = 2.92 (1.61-4.29).ConclusionsWe found that the G allele of rs2228527 and the G allele of rs2228529 within NER gene, interaction between rs2228529 and current smoking were all associated with increased NMSC risk.

show abstract

Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer

Cited by 5 publications

References 20 publications

<em>ERCC1</em> rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations

<em>ERCC1</em> rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations

Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis

A case-control study on association of nucleotide excision repair polymorphisms and its interaction with environment factors with the susceptibility to non-melanoma skin cancer

Contact Info

Product

Resources

About